---
title: "CHENGDA PHARMA: Elected Ge Jianli as Chairman"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265506957.md"
description: "36Kr learned that CHENGDA PHARMA announced that the board meeting agreed to elect Ge Jianli as the chairman of the company and the director representing the company's executive affairs, agreed to appoint Lu Gang as the general manager, and appointed Peng Zhiyong, Huang Honglin, Lu Jin, Yang Xiaojing, Hu Bao, and Zhao Minwei as deputy general managers, and appointed Fei Chao as the financial director"
datetime: "2025-11-12T11:31:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265506957.md)
  - [en](https://longbridge.com/en/news/265506957.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265506957.md)
generator: "portal-rs"
---

# CHENGDA PHARMA: Elected Ge Jianli as Chairman

36Kr learned that CHENGDA PHARMA announced that the board meeting agreed to elect Ge Jianli as the chairman of the company and the director representing the company's executive affairs, agreed to appoint Lu Gang as the general manager, and appointed Peng Zhiyong, Huang Honglin, Lu Jin, Yang Xiaojing, Hu Bao, and Zhao Minwei as deputy general managers, and appointed Fei Chao as the financial director

### Related Stocks

- [301201.CN](https://longbridge.com/en/quote/301201.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [Nasdaq Futures Plunge as Rising Bond Yields Drive Chip Selloff](https://longbridge.com/en/news/296216952.md)
- [Flash Sports & Media faces Nasdaq trading suspension over listing rule breach](https://longbridge.com/en/news/296655108.md)
- [OncoZenge registers 772,797 shares in directed issue after SEK 5 million payment from Sichuan Yangtian](https://longbridge.com/en/news/296607308.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**